Equity-Method Investment - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2021	Jul. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Equity method investment			$ 58,131,000	$ 58,131,000	$ 0
Loss from equity method investments				1,325,000	$ 0	$ 0
AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment			$ 58,100,000	$ 58,100,000
Equity Method Investment, Ownership Percentage			33.33%	33.33%
Investment Owned, at Fair Value		$ 62,900,000
Loss from equity method investments				$ 2,900,000
Investments in and Advances to Affiliates, at Fair Value, Gross Reductions			$ 1,800,000
AvenCell [Member] | Measurement Input, Option Volatility [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities measurement input, percentage		76.00%
AvenCell [Member] | Measurement Input Option Subsequent Financing [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities measurement input, percentage		75.00%
AvenCell [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities measurement input, percentage		11.00%
Sparing Vision [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value	$ 14,800,000
Sparing Vision [Member] | Series A2 Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Number of preferred stock received	83,316
Sparing Vision [Member] | Measurement Input, Option Volatility [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities measurement input, percentage	90.00%
Sparing Vision [Member] | Measurement Input Option, Rate of Return [Member]
Schedule of Equity Method Investments [Line Items]
Equity securities measurement input, percentage	65.00%
Kyverna Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value			$ 10,000,000.0	$ 10,000,000.0
Kyverna Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Number of preferred stock received				3,739,515
Fair value of stock received				$ 7,000.0
Number of stock additionally invested				1,602,649
Cash consideration received on sale of common stock				$ 3,000,000.0
Preferred Stock Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage		33.33%
Preferred Stock Purchase Agreement [Member] | Cellex and BXLS [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage		66.67%